NCT06212609 Optimized and Personalized Trans-cranial Brain Stimulation in Partial Refractory Epilepsies
| NCT ID | NCT06212609 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Transcranial Electric Stimulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2023-12-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Epilepsy is one of the most common neurological diseases, affecting between 0.5% and 1% of the general population. Therefore, new diagnostic and treatment methods are having a big impact on society. Epilepsy is also one of the most commonly diagnosed pediatric neurological disorders, with long-term implications for the quality of life of those affected and their relatives. In only two-thirds of cases, seizures can be adequately controlled with anticonvulsant drug therapy. For other patients with a drug-resistant focal epilepsy (up to around 2 million in Europe) epilepsy surgery is currently the most effective treatment. However, only 15-20% of these drug-resistant patients are eligible for epilepsy surgery. This is either because the cortical epileptogenic zone cannot be localized with sufficient precision with standard diagnostic means, or because the epileptogenic zone overlaps meaningful cortical areas, so that it cannot be surgically removed without considerable neurological deficit.
Eligibility Criteria
Inclusion Criteria: * Any patient, male or female aged 1 to 18, with refractory partial epilepsy considered potentially surgical according to the definition of ILAE. Drug-resistant epilepsy can be defined as the failure of adequate therapeutic trials of two antiepileptics (either monotherapy or in combination) so that the patient is free from seizures on a lasting basis. * Any epileptic patient with interictal epileptic spikes on his standard or High Resolution EEG and or on the Magnetoencephalography examination * Any epileptic patient undergoing a structural MRI * Any patient who has agreed to participate in the PerEpi 1 study allowing the optimization of the location of epileptic sources and the modelling of the optimization of the parameters of transcranial electrical stimulation * Patients who have at least 4 seizures per month Exclusion Criteria: * Patient not meeting the age criteria * And/or presenting generalized epilepsy * And/or presenting diffuse interictal peaks and/or presenting a serious alteration of the general condition and vital functions * And/or in the event of refusal by one of the parents or the child * Pregnant, parturient or breastfeeding woman. * Contraindication to the use of mc-tDCS stimulation without seizure
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06212609 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 18 Years, studying Transcranial Electric Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06212609 currently recruiting?
Yes, NCT06212609 is actively recruiting participants. Contact the research team at fabrice.wallois@u-picardie.fr for enrollment information.
Where is the NCT06212609 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT06212609 clinical trial?
NCT06212609 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 20 participants.